Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical... | February 23, 2022

Related Keywords

United States ,Wills Eye Hospital ,Pennsylvania ,Palo Alto ,Philadelphia ,Jason Ehrlich ,Victor Perlroth ,Carl Regillo ,Retina Service At Wills Eye Hospital ,Kodiak Sciences Inc ,Nasdaq ,Kodiak Sciences ,Chief Executive ,Retina Service ,Chief Medical Officer ,Chief Development Officer ,Antibody Biopolymer Conjugate ,Trial Identifier ,Trial Identifiers ,Kodiak Sciences Inc Stock Exchange ,News ,Information ,Press Release ,Halo ,022 ,Ciences ,Oday ,Nnounced ,Results ,Rom ,Its ,Ctive ,Hase Kod Us50015m1099 ,